Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Adam Cribbs has been awarded a prestigious MRC Career Development Award to further his research to identify therapeutic targets for multiple myeloma.

Adam Cribbs

Multiple myeloma (MM) is a cancer of plasma cells that has a varied response rate to treatment and a survival rate of 4-5 years. Poor survival has been attributed to drug resistance therefore identification of novel therapeutic targets for MM that overcome drug resistance is critical.

The MRC Career Development Awards, which are offered to support talented researchers to lead their own research, will enable Adam to build on his research interests in systems biology, immunology and epigenetics.

Specifically, he will develop novel, cost-effective multiplexed single-cell technologies that will provide an understanding of the relationship between the immune system and the MM tumour macroenvironment.

Commenting on his award Adam said: “I’m so pleased to have been offered the MRC award. We need to understand the cellular mechanisms that contribute to drug resistance within MM to be able to deliver better treatments. This award reinforces my belief that in time we will be able to expand the number of potential drug targets for MM, improving quality and longevity of life for patients.”

Similar stories

T-cell coreceptors are well endowed—with kinases!

The kinase occupancy of CD4 and CD8 coreceptors is high, according to a new study published in PNAS.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Dr Alex Clarke wins Emerging Leaders Prize for lupus research

Alex is one of three exceptional lupus researchers that have been announced as winners of the Medical Research Foundation’s sixth Emerging Leaders Prize.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.

Study reveals new evidence on rare blood-clotting condition after covid-19 vaccination

Researchers from NDORMS at the University of Oxford have investigated claims that some adenovirus-based COVID-19 vaccines increase the risk of rare blood clots compared to their mRNA-based counterparts.